GlycoMimetics Inc (NASDAQ:GLYC) Shares Purchased by Swiss National Bank

Swiss National Bank increased its stake in shares of GlycoMimetics Inc (NASDAQ:GLYC) by 2.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 64,200 shares of the biotechnology company’s stock after purchasing an additional 1,300 shares during the quarter. Swiss National Bank owned 0.15% of GlycoMimetics worth $765,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Dimensional Fund Advisors LP lifted its holdings in GlycoMimetics by 58.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 617,420 shares of the biotechnology company’s stock valued at $5,847,000 after acquiring an additional 228,664 shares during the period. BNP Paribas Arbitrage SA acquired a new stake in GlycoMimetics in the first quarter valued at $88,000. Candriam Luxembourg S.C.A. acquired a new stake in GlycoMimetics in the first quarter valued at $915,000. Asymmetry Capital Management L.P. acquired a new stake in GlycoMimetics in the first quarter valued at $1,707,000. Finally, DekaBank Deutsche Girozentrale lifted its holdings in GlycoMimetics by 22.9% in the first quarter. DekaBank Deutsche Girozentrale now owns 13,400 shares of the biotechnology company’s stock valued at $200,000 after acquiring an additional 2,500 shares during the period.

A number of equities research analysts have commented on the company. HC Wainwright reduced their target price on GlycoMimetics from $23.00 to $18.00 and set a “buy” rating for the company in a report on Monday, August 5th. BidaskClub cut GlycoMimetics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 24th. Piper Jaffray Companies cut GlycoMimetics from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $20.00 to $6.00 in a research report on Sunday, August 4th. Jefferies Financial Group cut GlycoMimetics from a “buy” rating to a “hold” rating in a research report on Monday, August 5th. Finally, Zacks Investment Research upgraded GlycoMimetics from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $13.45.

In related news, major shareholder Bvf Partners L. P/Il acquired 1,668,746 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The stock was purchased at an average price of $3.18 per share, for a total transaction of $5,306,612.28. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Daniel M. Junius acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The shares were bought at an average price of $3.18 per share, with a total value of $31,800.00. Following the transaction, the director now owns 18,000 shares in the company, valued at approximately $57,240. The disclosure for this purchase can be found here. Company insiders own 26.80% of the company’s stock.

Shares of GLYC stock traded up $0.13 during mid-day trading on Friday, reaching $4.61. The stock had a trading volume of 4,686 shares, compared to its average volume of 652,654. GlycoMimetics Inc has a 12-month low of $2.64 and a 12-month high of $14.81. The company has a market cap of $198.57 million, a P/E ratio of -3.90 and a beta of 2.71. The business has a 50-day simple moving average of $4.73 and a 200 day simple moving average of $10.20. The company has a current ratio of 17.54, a quick ratio of 17.54 and a debt-to-equity ratio of 0.02.

GlycoMimetics (NASDAQ:GLYC) last posted its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). Research analysts anticipate that GlycoMimetics Inc will post -1.51 EPS for the current year.

About GlycoMimetics

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML.

See Also: Buyback

Want to see what other hedge funds are holding GLYC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlycoMimetics Inc (NASDAQ:GLYC).

Institutional Ownership by Quarter for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.